Who are Adalimumab PFS and Pen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abrilada, Humira, Adalimumab, etanercept, infliximab, Etanercept + Methotrexate, TDM-based infliximab intravenous therapy, Adalimumab with methotrexate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adalimumab-pfs-and-pen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Adalimumab PFS and Pen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adalimumab PFS and Pen (Adalimumab PFS and Pen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-alpha inhibitor. Area: Immunology.

phase 2 TNF-alpha inhibitor TNF-alpha Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Adalimumab PFS and Pen (Adalimumab PFS and Pen) — Samsung Bioepis Co., Ltd.. TNF-alpha inhibitor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adalimumab PFS and Pen TARGET	Adalimumab PFS and Pen	Samsung Bioepis Co., Ltd.	phase 2	TNF-alpha inhibitor	TNF-alpha
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Adalimumab, etanercept, infliximab	Adalimumab, etanercept, infliximab	University of Padova	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)
Etanercept + Methotrexate	Etanercept + Methotrexate	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	TNF inhibitor + DMARD combination	TNF-alpha receptor (etanercept); dihydrofolate reductase (methotrexate)
TDM-based infliximab intravenous therapy	TDM-based infliximab intravenous therapy	Asan Medical Center	marketed	TNF-alpha inhibitor	TNF-alpha (Tumor Necrosis Factor-alpha)
Adalimumab with methotrexate	Adalimumab with methotrexate	Pfizer	marketed	TNF-alpha inhibitor + DMARD combination	TNF-alpha; dihydrofolate reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-alpha inhibitor class)

Abbott · 4 drugs in this class
Centre for Human Drug Research, Netherlands · 2 drugs in this class
Samsung Bioepis Co., Ltd. · 2 drugs in this class
Alvotech Swiss AG · 2 drugs in this class
UCB Pharma · 2 drugs in this class
Celltrion · 2 drugs in this class
AbbVie (prior sponsor, Abbott) · 2 drugs in this class
Assistance Publique Hopitaux De Marseille · 1 drug in this class
Asan Medical Center · 1 drug in this class
Carmel Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adalimumab PFS and Pen — Competitive Intelligence Brief. https://druglandscape.com/ci/adalimumab-pfs-and-pen. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab